Solara Active Pharma Sciences has announced the reconstitution of its Management Committee following a board meeting held on December 17, 2025. The company communicated this development to BSE Limited and National Stock Exchange of India Limited under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Board Meeting Details

The Board of Directors approved the reconstitution of the Management Committee during their meeting on December 17, 2025. The decision was made to enhance governance structure and operational efficiency of the pharmaceutical company.

Management Committee Composition

The reconstituted Management Committee comprises three key members representing different levels of the organizational hierarchy, ensuring comprehensive oversight and decision-making capabilities.

Corporate Structure

The Management Committee reconstitution reflects the company's commitment to maintaining robust governance standards. Mr. Arun Kumar Pillai will lead the committee as Chairperson in his capacity as Non-Executive Director, while the Managing Director & CEO and Chief Financial Officer will serve as key members.

Regulatory Compliance

Solara Active Pharma Sciences has fulfilled its disclosure obligations by informing both major stock exchanges about the committee reconstitution. The company operates from its corporate office at TICEL Bio Park, Chennai, and maintains its registered office in Navi Mumbai.

The reconstitution demonstrates the company's ongoing efforts to strengthen its management structure and ensure effective oversight of operations across its pharmaceutical business segments.

Solara Active Pharma Sciences has successfully completed a U.S. Food and Drug Administration (FDA) inspection at its Mangalore manufacturing facility, maintaining its Current Good Manufacturing Practice (CGMP) compliance status. This development ensures continued regulatory approval for the company's pharmaceutical manufacturing operations at the facility.

Inspection Details

The FDA inspection, conducted from August 25th to 29th, 2025, resulted in the issuance of an Establishment Inspection Report (EIR) on November 18th, 2025. The inspection classification for the facility was determined to be "Voluntary Action Indicated (VAI)," and the inspection was concluded as closed.

Key Highlights

• The FDA issued two Form 483 inspectional observations, which were procedural in nature.
• Solara submitted a formal response to the FDA within the specified timeline.
• The successful inspection outcome demonstrates Solara's commitment to regulatory excellence and world-class quality standards.

Management Commentary

Sandeep Rao, MD & CEO of Solara Active Pharma Sciences, commented on the inspection outcome: "The inspection outcome demonstrates our commitment to regulatory excellence at our global manufacturing sites and relentless focus on world-class quality and compliance, which remains a key pillar of our growth strategy."

Facility Overview

The Mangalore facility is a multi-product API manufacturing site equipped with:

• Several independent production blocks
• Related packaging sections
• Approvals from various regulatory authorities including US FDA, EDQM, HPRA, TGA, WHO, PMDA, and MFDS, Korea

This successful FDA inspection reinforces Solara Active's position as a leading pure-play Active Pharmaceutical Ingredient (API) provider, supporting its growth strategy in the global pharmaceutical market.

About Solara Active Pharma Sciences Ltd

Solara Active Pharma Sciences Ltd is a pure-play global API manufacturer with:

• 6 manufacturing facilities
• 1 R&D Centre
• A diverse portfolio of high-value Commercial APIs
• Contract manufacturing services

The company's API facilities are approved by various international regulatory agencies, positioning it strongly in the pharmaceutical industry.